Mustang Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MBIO research report →
Price Chart
About the company
Mustang Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
- CEO
- Manuel Litchman
- IPO
- 2017
- Employees
- 4
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on MBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.49M
- P/E
- -1.03
- PEG
- -0.04
- P/S
- 0.00
- P/B
- 0.41
- EV/EBITDA
- 3.85
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -34.23%
- ROIC
- -45.77%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-41,000+0.0%
- Op Income
- $-2,432,000
- Net Income
- $-1,921,000+87.8%
- EPS
- $-0.39+84.8%
- OCF Growth
- +53.9%
- FCF Growth
- +53.9%
- 52W High
- $1.85
- 52W Low
- $0.46
- 50D MA
- $0.55
- 200D MA
- $0.75
- Beta
- 2.09
- RSI (14)
- 33
- Avg Volume
- 29.05K
No earnings-call transcripts are available for MBIO yet.
- Free Float
- 85.0%
- Shares Outstanding
- 7.58M
- Float Shares
- 6.44M
of shares held by institutions
22 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Kestra Advisory Services, LLC | 196.99K | ▲ 20.95K |
| Blackrock, Inc. | 84.75K | 0 |
| Citadel Advisors LLC | 59.46K | ▲ 6.26K |
| Vanguard Group Inc | 57.86K | 0 |
| Geode Capital Management, LLC | 42.24K | ▼ 50.55K |
| Cfo4life Group, LLC | 33.51K | ▲ 13.05K |
| Vanguard Fiduciary Trust Co | 32.12K | 0 |
| Vanguard Capital Management LLC | 25.70K | 0 |
| Xtx Topco Ltd | 14.65K | ▲ 14.65K |
| Virtu Financial LLC | 14.36K | ▲ 14.36K |
| Two Sigma Securities, LLC | 13.74K | ▲ 13.74K |
| Susquehanna International Group, Llp | 13.66K | ▲ 13.66K |
Held by 7 ETFs
Biggest fund positions in MBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 24, 26 | Litchman Manuel MD | other | 19 |
| Jan 2, 26 | Fortress Biotech, Inc. | other | 278,385 |
| Dec 30, 25 | Herskowitz Neil | sell | 247 |
| Dec 30, 25 | Chill Adam J. | sell | 4 |
| Dec 30, 25 | Jin David | buy | 247 |
| Sep 29, 25 | Fortress Biotech, Inc. | other | 59,334 |
| Apr 24, 25 | Litchman Manuel MD | other | 27 |
| Mar 31, 25 | Fortress Biotech, Inc. | other | 67,806 |
| Dec 31, 24 | Fortress Biotech, Inc. | other | 0 |
| Oct 23, 24 | Jin David | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MBIO coverage
Recent articles, reports, and earnings notes.
No research on MBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MBIO report →MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks
globenewswire.com · Jun 9
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
globenewswire.com · May 14
IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.
globenewswire.com · May 12
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection
globenewswire.com · May 12
MindBio Announces Closing of Private Placement
thenewswire.com · Apr 1
MindBio Announces Upsize to Private Placement up to $1.5 Million
thenewswire.com · Mar 19
Critical Contrast: Mustang Bio (NASDAQ:MBIO) & AstraZeneca (NASDAQ:AZN)
defenseworld.net · Feb 27
MindBio Announces Private Placement to Raise up to $650,000
thenewswire.com · Feb 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.